The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology to include ...
Urinary system tumors are a group of tumors that occur in the kidney, ureter, bladder and urethra, of which bladder cancer is the most common, followed by ...
Johnson & Johnson gained Inlexzo, formerly known as TAR-200, when it acquired privately held Taris Biomedical in 2019. The deal gave J&J a treatment it says could change way the “non-muscle invasive” ...
Approval is for combination use with pembrolizumab both before and after surgery. HealthDay News — The U.S. Food and Drug Administration has approved Padcev (enfortumab vedotin-ejfv), a Nectin-4 ...
Vignesh Packiam discusses an AI biomarker developed for nonmuscle invasive bladder cancer that addresses the critical challenge of risk stratification in this highly heterogeneous disease. Christopher ...
Muscle-invasive bladder cancer (MIBC) is a biologically heterogeneous disease with variable prognosis after radical cystectomy. While conventional clinicopathological parameters offer limited ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results